세계의 류마티스성 다발근통 시장 보고서(2025년)

Polymyalgia rheumatica (PMR) is an inflammatory condition that primarily affects older adults, leading to muscle pain and stiffness, especially in the shoulders, hips, and neck. It is characterized by aching and swelling in the muscles around the shoulders and hips, making it difficult to move and perform daily activities.

The primary treatment types for polymyalgia rheumatica include corticosteroids, nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and biologics. Corticosteroids are the most common treatment for PMR, helping to reduce inflammation and relieve symptoms by mimicking adrenal hormones. These medications can be administered orally, intravenously, or subcutaneously, and they are used for various patient types, including adults, geriatrics, and pediatrics. Distribution occurs through different channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The polymyalgia rheumatica market research report is one of a series of new reports from The Business Research Company that provides polymyalgia rheumatica market statistics, including the polymyalgia rheumatica industry global market size, regional shares, competitors with the polymyalgia rheumatica market share, detailed polymyalgia rheumatica market segments, market trends, and opportunities, and any further data you may need to thrive in the polymyalgia rheumatica industry. This polymyalgia rheumatica market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The polymyalgia rheumatica market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historical period can be attributed to factors such as increasing awareness among healthcare practitioners, the rising use of corticosteroids, the growth of specialty clinics, the introduction of biologic therapies, and increased healthcare budgets.

The polymyalgia rheumatica market size is expected to see strong growth in the next few years. It will grow to $1.73 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period is expected to be driven by the growing adoption of biologics, the expansion of precision medicine, accelerated drug approvals, broader reimbursements, and the expansion of clinical trials. Key trends for the forecast period include the development of combination therapies, advancements in personalized medicine, the growth of precision medicine, the integration of electronic health records, and improvements in biomarkers.

The increasing demand for personalized medicine is expected to drive the growth of the polymyalgia rheumatica market in the future. Personalized medicine involves medical treatments customized to an individual's genetic profile, lifestyle, and specific health conditions, leading to more effective outcomes. The demand for this approach is fueled by advancements in genetic research, growing patient expectations for tailored treatments, and improvements in diagnostic technologies. Through genetic research, a better understanding of genetic variations has allowed for treatments that target specific genetic markers. Personalized medicine helps identify the most effective drugs based on a patient's characteristics, leading to safer and more efficient treatment plans. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. This growth in personalized medicine is driving the expansion of the polymyalgia rheumatica market.

The growth of telemedicine services is also expected to contribute to the growth of the polymyalgia rheumatica market. Telemedicine leverages digital communication technologies such as video calls, phone calls, and online messaging to offer remote medical consultations, diagnoses, treatments, and follow-up care, eliminating the need for in-person visits. The rise in telemedicine is driven by increasing demand for convenient healthcare options and cost-effective solutions. Patients, particularly for non-urgent consultations, are seeking more convenient alternatives that telemedicine offers. These services help manage polymyalgia rheumatica (PMR) by enabling remote monitoring of symptoms, medication management, and regular follow-ups, all essential for controlling chronic pain and inflammation. For instance, according to the Australian Bureau of Statistics, in 2022-23, 87.7% of people used telehealth consultations, and this figure rose to 89.2% in 2023-24. Thus, the growth of telemedicine is fueling the expansion of the polymyalgia rheumatica market.

Major companies are focusing on developing advanced drugs, such as interleukin-6 (IL-6) receptor blockers, to offer more targeted and effective treatment options. IL-6 receptor blockers are biological drugs that target IL-6, a pro-inflammatory cytokine involved in autoimmune diseases. By blocking IL-6, these drugs help reduce inflammation and alleviate symptoms, thus improving the quality of life for PMR patients. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, announced that the FDA approved Kevzara (sarilumab) for treating polymyalgia rheumatica in adults who have not responded to corticosteroids or cannot tolerate tapering off them. Kevzara is the first and only biologic approved for this condition, and it works by inhibiting IL-6 signaling. In a study, 28.3% of patients treated with sarilumab achieved sustained remission after 52 weeks, compared to 10.3% of those on a placebo. Kevzara is administered via subcutaneous injection every two weeks and is also approved for moderately to severely active rheumatoid arthritis. Sanofi's stock (SNY) is currently trading at $54.13 on NASDAQ.

Major players in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women's Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital.

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in polymyalgia rheumatica report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the polymyalgia rheumatica market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The polymyalgia rheumatica market consists of revenues earned by entities by providing services such as medication management, pain management, laboratory testing, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyalgia rheumatica market includes sales of disease-modifying anti-rheumatic drugs, calcium and vitamin D supplements, assistive devices, and physical therapy aids. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Polymyalgia Rheumatica Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on polymyalgia rheumatica market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for polymyalgia rheumatica ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The polymyalgia rheumatica market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Corticosteroids; Nonsteroidal Anti-Inflammatory Drugs; Disease-Modifying Antirheumatic Drugs; Biologics
• 2) By Route Of Administration: Oral; Intravenous; Subcutaneous
• 3) By Patient Type: Adult; Geriatric; Periatric
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
• 2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Aspirin; Celecoxib
• 3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate; Leflunomide; Sulfasalazine; Hydroxychloroquine
• 4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin-6 (IL-6) Inhibitors; B-Cell Inhibitors; Janus Kinase (JAK) Inhibitors
• Companies Mentioned: AbbVie Inc.; Sanofi S.A.; Eli Lilly and Co.; Regeneron Pharmaceuticals Inc.; Mount Sinai
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Polymyalgia Rheumatica Market Characteristics

3. Polymyalgia Rheumatica Market Trends And Strategies

4. Polymyalgia Rheumatica Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Polymyalgia Rheumatica Growth Analysis And Strategic Analysis Framework

• 5.1. Global Polymyalgia Rheumatica PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Polymyalgia Rheumatica Market Growth Rate Analysis
• 5.4. Global Polymyalgia Rheumatica Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Polymyalgia Rheumatica Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Polymyalgia Rheumatica Total Addressable Market (TAM)

6. Polymyalgia Rheumatica Market Segmentation

• 6.1. Global Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Nonsteroidal Anti-Inflammatory Drugs
• Disease-Modifying Antirheumatic Drugs
• Biologics
• 6.2. Global Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• 6.3. Global Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Geriatric
• Periatric
• 6.4. Global Polymyalgia Rheumatica Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Polymyalgia Rheumatica Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• Hydrocortisone
• Dexamethasone
• 6.6. Global Polymyalgia Rheumatica Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Naproxen
• Aspirin
• Celecoxib
• 6.7. Global Polymyalgia Rheumatica Market, Sub-Segmentation Of Disease-Modifying Antirheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methotrexate
• Leflunomide
• Sulfasalazine
• Hydroxychloroquine
• 6.8. Global Polymyalgia Rheumatica Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin-6 (IL-6) Inhibitors
• B-Cell Inhibitors
• Janus Kinase (JAK) Inhibitors

7. Polymyalgia Rheumatica Market Regional And Country Analysis

• 7.1. Global Polymyalgia Rheumatica Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Polymyalgia Rheumatica Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Polymyalgia Rheumatica Market

• 8.1. Asia-Pacific Polymyalgia Rheumatica Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Polymyalgia Rheumatica Market

• 9.1. China Polymyalgia Rheumatica Market Overview
• 9.2. China Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Polymyalgia Rheumatica Market

• 10.1. India Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Polymyalgia Rheumatica Market

• 11.1. Japan Polymyalgia Rheumatica Market Overview
• 11.2. Japan Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Polymyalgia Rheumatica Market

• 12.1. Australia Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Polymyalgia Rheumatica Market

• 13.1. Indonesia Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Polymyalgia Rheumatica Market

• 14.1. South Korea Polymyalgia Rheumatica Market Overview
• 14.2. South Korea Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Polymyalgia Rheumatica Market

• 15.1. Western Europe Polymyalgia Rheumatica Market Overview
• 15.2. Western Europe Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Polymyalgia Rheumatica Market

• 16.1. UK Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Polymyalgia Rheumatica Market

• 17.1. Germany Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Polymyalgia Rheumatica Market

• 18.1. France Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Polymyalgia Rheumatica Market

• 19.1. Italy Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Polymyalgia Rheumatica Market

• 20.1. Spain Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Polymyalgia Rheumatica Market

• 21.1. Eastern Europe Polymyalgia Rheumatica Market Overview
• 21.2. Eastern Europe Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Polymyalgia Rheumatica Market

• 22.1. Russia Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Polymyalgia Rheumatica Market

• 23.1. North America Polymyalgia Rheumatica Market Overview
• 23.2. North America Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Polymyalgia Rheumatica Market

• 24.1. USA Polymyalgia Rheumatica Market Overview
• 24.2. USA Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Polymyalgia Rheumatica Market

• 25.1. Canada Polymyalgia Rheumatica Market Overview
• 25.2. Canada Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Polymyalgia Rheumatica Market

• 26.1. South America Polymyalgia Rheumatica Market Overview
• 26.2. South America Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Polymyalgia Rheumatica Market

• 27.1. Brazil Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Polymyalgia Rheumatica Market

• 28.1. Middle East Polymyalgia Rheumatica Market Overview
• 28.2. Middle East Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Polymyalgia Rheumatica Market

• 29.1. Africa Polymyalgia Rheumatica Market Overview
• 29.2. Africa Polymyalgia Rheumatica Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Polymyalgia Rheumatica Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Polymyalgia Rheumatica Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Polymyalgia Rheumatica Market Competitive Landscape And Company Profiles

• 30.1. Polymyalgia Rheumatica Market Competitive Landscape
• 30.2. Polymyalgia Rheumatica Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mount Sinai Overview, Products and Services, Strategy and Financial Analysis

31. Polymyalgia Rheumatica Market Other Major And Innovative Companies

• 31.1. NYU Langone Health
• 31.2. Mayo Foundation for Medical Education and Research
• 31.3. Hartford HealthCare
• 31.4. Horizon Therapeutics plc
• 31.5. Massachusetts General Hospital
• 31.6. Brigham and Women's Hospital
• 31.7. Stanford Health Care
• 31.8. University Hospitals Bristol NHS Foundation Trust
• 31.9. Circle Health Group Ltd.
• 31.10. Siloam Hospital
• 31.11. UC San Diego Health
• 31.12. Vejthani Hospital
• 31.13. Sparrow Pharmaceuticals Inc.
• 31.14. Johns Hopkins Arthritis Center
• 31.15. Upstate University Hospital

32. Global Polymyalgia Rheumatica Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Polymyalgia Rheumatica Market

34. Recent Developments In The Polymyalgia Rheumatica Market

35. Polymyalgia Rheumatica Market High Potential Countries, Segments and Strategies

• 35.1 Polymyalgia Rheumatica Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Polymyalgia Rheumatica Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Polymyalgia Rheumatica Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer